The Pike Lab
@pike_lab
Followers
214
Following
36
Media
4
Statuses
57
The Pike Laboratory led by Luke Pike @MSKCancerCenter @MSK_RadOnc seeks to improve care for patients afflicted by brain metastasis.
New York
Joined July 2022
@JCO_ASCO: TURBO-NSCLC ( https://t.co/kkBrG0OIfr) was a multi-institutional cohort study of 317 treatment-naive EGFR or ALK NSCLC pts with Brain Mets who received TKI w/wo up-front SRS. SRS was associated with superior CNS control. @MSK_RadOnc
@MSKCancerCenter
ascopubs.org
PURPOSENewer-generation tyrosine kinase inhibitors (TKIs) for non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrang...
0
2
12
Brain metastasis is an uncommon but devastating event for pts with colorectal cancer. In work led by Drs. Gui and Walch @hswalch, we identify genomic features, present at initial diagnosis, that may help identify pts likely to develop BM. @MSKCancerCenter
academic.oup.com
AbstractBackground. Brain metastasis (BM) in colorectal cancer (CRC) is a rare event that undermines longevity and neurocognitive function. However, the mo
1
9
29
Consensus Radiation Treatment Planning Guidelines Using (68)Ga-DOTATATE PET/CT For Resected Meningiomas - International Journal of Radiation Oncology, Biology, Physics https://t.co/ZmIcEhZ8ul Kudos to @joshuapalmermd @HaleyPerlow for leading this effort!
0
21
56
The management of brain metastases in EGFR-variant and ALK-positive NSCLC patients remains uncertain, with evidence suggesting that upfront stereotactic radiosurgery (SRS) offers better local control and delays CNS progression.
2
34
84
I’m pleased to share our summary of the clinical evidence on the use of TKIs and SRS in EGFR or ALK+ NSCLC! We need better biomarkers to select patients for treatment de-escalation. @JAMAOnc @MSKCancerCenter @MSK_RadOnc
https://t.co/rV54PZNhJE
jamanetwork.com
This clinical evidence synopsis summarizes the results of 3 multi-institutional cohort studies that compare tyrosine kinase inhibitors with or without stereotactic radiosurgery in patients with...
3
15
40
The ICON-RT study is now active at MSK! In this ph2 RCT, we seek to test a treatment de-escalation strategy for EGFR+LC Brain Mets through Intracranial CONsolidation with RT after a lead-in of osimertinib-based therapy! @MSKCancerCenter @MSK_RadOnc
2
1
14
I'm pleased to share work led by Ben Gaeta and Jordan Eichholz @jeeichholz on CNS outcomes and genomic correlates of KRAS mutant NSCLC Brain Mets treated with SRS, published in the Red J! @MSKCancerCenter @MSK_RadOnc @IJROBP
1
5
11
@HockemeyerKate @MSKCancerCenter @MSK_RadOnc @Cancers_MDPI An congratulations to @HockemeyerKate for making the cover! https://t.co/BE5pvqBHYa
0
0
2
I am very pleased to partner with @HarbingerHlth in our combined goal of making blood-based early cancer detection a reality! @MSKCancerCenter @MSK_RadOnc
https://t.co/t4b4TTiC1w
0
0
7
From the November issue: Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection. https://t.co/F4N9TQlXe1 By Peter Mazzone, @velculescu,@pike_lab @ClevelandClinic @hopkinskimmel @MSKCancerCenter @DELFIDiagnostic
0
4
13
Very fine review written by Dr. @HockemeyerKate , one of our star resident physicians at @MSKCancerCenter @MSK_RadOnc on the management of lung cancer brain metastasis, now online at @Cancers_MDPI .
mdpi.com
Lung cancer, both non-small cell and small cell, harbors a high propensity for spreading to the central nervous system. Radiation therapy remains the backbone of the management of brain metastases....
1
4
15
We're hiring again this year for an MSK CNS Fellow! Please directly inquire if interested! https://t.co/5pbkyVFxsL
careers.astro.org
A new
0
0
3
5
6
98
Proud to see work led by Chengcheng Gui and @hswalch published in @TheJNS in which we examine radiosurgical outcomes in a large cohort of CRC BM patients. Dose matters here and we identify putative genomic biomarkers. @MSKCancerCenter @MSK_RadOnc
0
0
10
Clinical Outcomes and Targeted Genomic Analysis of Renal Cell Carcinoma Brain Metastases Treated with Stereotactic Radiosurgery - European Urology Oncology
0
2
7
Online now at @EurUrolOncol is exciting work by @JenniferMaMD @LukedelBalzo @hswalch, co-mentored with @KotechaMD. The largest series of RCC BM genomics, identifying genomic biomarkers correlated with CNS outcome after SRS. @MSKCancerCenter @MSK_RadOnc
https://t.co/12vK5Nhu2k
0
3
11
Any role of up-front SRS in lung pts with brain Mets and EGFR or ALK targetable mutations who is receiving the 3th generation TKIs? JCO July 24, 2024 SRS improves time to CNS progression, particularly for lesion > 1 cm OS is similar MDT and personalized approach are crucial.
0
11
45
A new multi-institution study from @pike_lab and colleagues in @JCO_ASCO finds adding up-front stereotactic radiosurgery improved time to CNS progression in patients with brain metastases from EGFR- and ALK-driven non-small cell lung cancer. #NSCLC
ascopubs.org
PURPOSENewer-generation tyrosine kinase inhibitors (TKIs) for non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrang...
0
4
19
🧠⚡️🫁☢️New in @JCO_ASCO from @pike_lab @Chad_Rusthoven: The addition of up-front #radiation #SRS to CNS-penetrant #TKI ⬆️time-to-CNS progression & local control (but not OS) in pts with brain mets from #EGFR #ALK-driven #NSCLC #lungcancer. #lcsm #radonc
https://t.co/0QcXj1cpQf
1
18
48